PD 81723

Drug Profile

PD 81723

Latest Information Update: 12 Jan 1996

Price : $50

At a glance

  • Originator Pfizer
  • Class Anti-ischaemics; Antiarrhythmics; Small molecules; Thiophenes
  • Mechanism of Action Adenosine A1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias; Ischaemic heart disorders

Most Recent Events

  • 12 Jan 1996 An animal study has been added to the Ischaemic Heart Disease pharmacodynamics section
  • 16 Jun 1995 Discontinued-Unspecified for Ischaemic heart disorders in USA (Unknown route)
  • 16 Jun 1995 No-Development-Reported-Unspecified for Arrythmias in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top